{"id":"NCT00988091","sponsor":"Ferring Pharmaceuticals","briefTitle":"Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee","officialTitle":"A 26 Week, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Single Intra-Articular Injection 1.2% Sodium Hyaluronate for Treatment of Painful Osteoarthritis of the Knee, With Optional 26-Week Open-Label Safety Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2010-10","completion":"2011-04","firstPosted":"2009-10-01","resultsPosted":"2012-06-04","lastUpdate":"2012-06-15"},"enrollment":596,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis of the Knee"],"interventions":[{"type":"DEVICE","name":"1.2% Sodium Hyaluronate","otherNames":["sodium hyaluronate"]},{"type":"DEVICE","name":"Buffered Saline","otherNames":["saline"]}],"arms":[{"label":"IA-SA","type":"PLACEBO_COMPARATOR"},{"label":"IA-BioHA","type":"EXPERIMENTAL"}],"summary":"Subjects with chronic osteoarthritis of the knee will be assigned to receive an injection of either 1.2% sodium hyaluronate or buffered saline to evaluate its effectiveness and safety for 26 weeks. After 26 weeks, subjects can elect to receive a second injection of 1.2% sodium hyaluronate and be followed for another 26 weeks.","primaryOutcome":{"measure":"Change From Baseline in the Visual Analogue Score (VAS) Pain Score of the 50-foot Walk Test at Week 26","timeFrame":"Day 0 (baseline) through Week 26","effectByArm":[{"arm":"IA-SA","deltaMin":-33.48,"sd":1.81},{"arm":"IA-BioHA","deltaMin":-28.15,"sd":1.82}],"pValues":[{"comp":"OG000 vs OG001","p":"0.034"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":24},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":298},"commonTop":["Arthralgia"]}}